#4-08E. Overcoming Refractory Dermatomyositis: The Promise of Brepocitinib (NEJM, 2026)

How can we overcome the dual challenges of refractory disease activity and severe steroid toxicity in managing dermatomyositis? This phase 3, randomized, double-blind, placebo-controlled trial evaluated brepocitinib, a novel oral TYK2-JAK1 inhibitor, in 241 adults with treatment-resistant dermatomyositis, comparing 30 mg and 15 mg daily doses against a placebo over 52 weeks. The study's most crucial clinical finding is that the 30 mg dose achieved a significantly higher Total Improvement Score and facilitated profound reductions in systemic glucocorticoid use compared to the placebo. However, a critical limitation to consider when appraising this study is that the trial design required background DMARD therapy to remain completely stable throughout the entire 52-week blinded period. This strict requirement limits generalizability, as real-world clinical practice typically involves tapering background immunosuppressants once adequate disease control is established. For practicing physicians, this research is exceptionally valuable because it presents a targeted oral therapy capable of aggressively managing both cutaneous and muscular symptoms in refractory patients, while actively providing a much-needed steroid-sparing strategy to prevent long-term morbidities.

Citation: Vleugels RA, Paik JJ, et al. A Phase 3 Trial of Brepocitinib in Dermatomyositis. The New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2503531

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.